Skip to content
OpenCapital
Get started

LivaNova LIVN Cardiopulmonary — Net revenue

Other segment segments

Neuromodulation
$151.79M+9.3%

Similar metrics at other companies

Boston Scientific logo
BSXCardiovascular — Net Sales
$3.5B+13.5%
Lantheus Holdings logo
LNTHCardiology — Revenue
$84.63M+6.8%
Medtronic logo
MDTCardiovascular — Net Sales
$3.8B+13.8%
Boston Scientific logo
BSXCardiovascular — Net sales of reportable segments
$3.5B+10.9%
Balchem logo
BCPCProduct Sales Revenue — Net Sales
$270.22M+8.1%
Cytokinetics logo
CYTKNet Product Revenue — Revenue
$4.79M—

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.31B+62.8%
Enterprise value$4.11B+58.0%
P/S3×+0.9×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's cardiopulmonary — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's cardiopulmonary — net revenue?
LivaNova (LIVN) reported cardiopulmonary — net revenue of $208.66M in Q1 2026.
How has LivaNova's cardiopulmonary — net revenue changed year-over-year?
LivaNova's cardiopulmonary — net revenue increased by 18.3% year-over-year, from $176.32M to $208.66M.
What is the long-term trend for LivaNova's cardiopulmonary — net revenue?
Over 4 years (2021 to 2025), LivaNova's cardiopulmonary — net revenue has grown at a 12.9% compound annual growth rate (CAGR), from $482.98M to $785.39M.
What does cardiopulmonary — net revenue mean?
Represents the total gross sales generated by the cardiopulmonary business segment after deducting returns, allowances, and discounts. This metric serves as a primary indicator of the segment's market demand and top-line growth performance.